Phaseline

Targets › NFYA

NFYA (Nuclear transcription factor Y subunit alpha): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2027.

Component of the sequence-specific heterotrimeric transcription factor (NF-Y) which specifically recognizes a 5'-CCAAT-3' box motif found in the promoters of its target genes. NF-Y can function as both an activator and a repressor, depending on its interacting cofactors. (UniProt, P23511)

Open in Phaseline: the race on NFYA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jing ZhouCeftazidime
Bacterial penicillin-binding protein inhibitor
NFYAPhase 4Ceftazidime-avibactamDec 2027

Conditions

Ceftazidime-avibactam (1)

Modalities

small molecule (1)

Companies

Jing Zhou (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.